<p>/PRNewswire/ -- Robbins LLP 提醒股东，代表在 2024 年 10 月 9 日至 2025 年 7 月 10 日期间购买或以其他方式获得 Capricor Therapeutics, Inc. (NASDAQ: CAPR) 证券的投资者提起了集体诉讼。Capricor 是一家临床阶段的生物技术公司，专注于开发变革性的细胞和外泌体基础的治疗方法，以治疗</p>
<p>杜氏肌营养不良症 (DMD) 及美国其他未满足医疗需求的疾病。其主要产品候选药物是 deramiocel，一种异体心脏球体衍生细胞。</p>
<p>欲了解更多信息，请提交表格，发送电子邮件给律师 Aaron Dumas, Jr.，或拨打电话 (800) 350-6003。</p>
<p><strong>指控：</strong> Robbins LLP 正在调查关于 Capricorn Therapeutics, Inc. (CAPR) 误导投资者有关 deramiocel 可行性的指控。</p>
<p>根据投诉，在集体诉讼期间，被告误导投资者有关 Capricor 的主要细胞治疗候选药物 deramiocel 用于治疗与 DMD 相关的心肌病。被告给出了错误的印象，认为他们可以获得 DMD 心肌病的首次批准，同时隐瞒了其 Phase 2 HOPE-2 试验研究中关于 deramiocel 的四年安全性和有效性数据的重大不利事实。这导致原告和其他股东以人为抬高的价格购买了 Capricor 的证券。</p>
<p>原告声称，在 2025 年 7 月 11 日，Capricor 发布了一份新闻稿，宣布其收到了 FDA 的完整回应信 (CRL)，拒绝了生物制品许可申请，特别指出未满足有效性实质证据的法定要求，并需要额外的临床数据。此外，CRL 提到了申请中化学、制造和控制部分的未解决事项。因此，Capricor 股票的价格从 2025 年 7 月 10 日的每股 11.40 美元下降至 2025 年 7 月 11 日的每股 7.64 美元。</p>
<p><strong>接下来怎么办</strong>：您可能有资格参与针对 Capricorn Therapeutics, Inc. 的集体诉讼。希望担任集体诉讼主原告的股东应联系该公司。主原告是代表其他集体成员指导诉讼的代表方。您不必参与案件即可有资格获得赔偿。如果您选择不采取任何行动，您可以保持缺席集体成员身份。欲了解更多信息，请点击此处。</p>
<p><strong><em>所有代理均按成功收费基础进行。股东无需支付任何费用或开支。</em></strong></p>
<p><strong>关于 Robbins LLP</strong>：作为股东权益诉讼的公认领导者，Robbins LLP 的律师和员工自 2002 年以来一直致力于帮助股东追回损失、改善公司治理结构，并追究公司高管的错误行为。</p>
<p>如果希望在针对 Capricorn Therapeutics, Inc. 的集体诉讼达成和解时收到通知，或在公司高管参与不当行为时免费接收警报，请立即注册 Stock Watch。</p>
<p>律师广告。过去的结果并不保证类似的结果。</p>
<p>www.robbinsllp.com</p>
<p>来源 Robbins LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzMwJk5ld3NJdGVtSWQ9TEEzODA2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MzAxMTIyUFJfTkVXU19VU1BSX19fX19MQTM4MDY0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzMwJk5ld3NJdGVtSWQ9TEEzODA2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MzAxMTIyUFJfTkVXU19VU1BSX19fX19MQTM4MDY0"/></p>

Capricor治疗

<p>Robbins LLP 宣布对在 2024 年 10 月 9 日至 2025 年 7 月 10 日期间购买 Capricor Therapeutics, Inc.（纳斯达克代码：CAPR）证券的投资者提起集体诉讼。诉讼指控 Capricor 在其主要产品 deramiocel 治疗杜氏肌营养不良症的可行性方面误导了投资者。在 FDA 对该药物批准的负面回应后，Capricor 的股价大幅下跌。股东可能有资格参与集体诉讼，除非获得赔偿，否则不收取任何费用</p>

<p>, /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating</p>
<div class="lb-trans"><p>/PRNewswire/ -- Robbins LLP 提醒股东，代表在 2024 年 10 月 9 日至 2025 年 7 月 10 日期间购买或以其他方式获得 Capricor Therapeutics, Inc. (NASDAQ: CAPR) 证券的投资者提起了集体诉讼。Capricor 是一家临床阶段的生物技术公司，专注于开发变革性的细胞和外泌体基础的治疗方法，以治疗</p>
</div><p>Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is deramiocel, an allogeneic cardiosphere-derived cells.</p>
<div class="lb-trans"><p>杜氏肌营养不良症 (DMD) 及美国其他未满足医疗需求的疾病。其主要产品候选药物是 deramiocel，一种异体心脏球体衍生细胞。</p>
</div><p>For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.</p>
<div class="lb-trans"><p>欲了解更多信息，请提交表格，发送电子邮件给律师 Aaron Dumas, Jr.，或拨打电话 (800) 350-6003。</p>
</div><p><strong>The Allegations:</strong> Robbins LLP is Investigating Allegations that Capricorn Therapeutics, Inc. (CAPR) Misled Investors Regarding the Viability of Deramiocel</p>
<div class="lb-trans"><p><strong>指控：</strong> Robbins LLP 正在调查关于 Capricorn Therapeutics, Inc. (CAPR) 误导投资者有关 deramiocel 可行性的指控。</p>
</div><p>According to the complaint, during the class period, defendants misled investors concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with DMD. Defendants gave the false impression that they could obtain first approval for DMD cardiomyopathy, while, at the same time, concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. This caused Plaintiff and other shareholders to purchase Capricor's securities at artificially inflated prices.</p>
<div class="lb-trans"><p>根据投诉，在集体诉讼期间，被告误导投资者有关 Capricor 的主要细胞治疗候选药物 deramiocel 用于治疗与 DMD 相关的心肌病。被告给出了错误的印象，认为他们可以获得 DMD 心肌病的首次批准，同时隐瞒了其 Phase 2 HOPE-2 试验研究中关于 deramiocel 的四年安全性和有效性数据的重大不利事实。这导致原告和其他股东以人为抬高的价格购买了 Capricor 的证券。</p>
</div><p>Plaintiff alleges that on July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the Biologics License Application specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. As a result, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.</p>
<div class="lb-trans"><p>原告声称，在 2025 年 7 月 11 日，Capricor 发布了一份新闻稿，宣布其收到了 FDA 的完整回应信 (CRL)，拒绝了生物制品许可申请，特别指出未满足有效性实质证据的法定要求，并需要额外的临床数据。此外，CRL 提到了申请中化学、制造和控制部分的未解决事项。因此，Capricor 股票的价格从 2025 年 7 月 10 日的每股 11.40 美元下降至 2025 年 7 月 11 日的每股 7.64 美元。</p>
</div><p><strong>What Now</strong>: You may be eligible to participate in the class action against Capricorn Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.</p>
<div class="lb-trans"><p><strong>接下来怎么办</strong>：您可能有资格参与针对 Capricorn Therapeutics, Inc. 的集体诉讼。希望担任集体诉讼主原告的股东应联系该公司。主原告是代表其他集体成员指导诉讼的代表方。您不必参与案件即可有资格获得赔偿。如果您选择不采取任何行动，您可以保持缺席集体成员身份。欲了解更多信息，请点击此处。</p>
</div><p><strong><em>All representation is on a contingency fee basis. Shareholders pay no fees or expenses.</em></strong></p>
<div class="lb-trans"><p><strong><em>所有代理均按成功收费基础进行。股东无需支付任何费用或开支。</em></strong></p>
</div><p><strong>About Robbins LLP</strong>: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.</p>
<div class="lb-trans"><p><strong>关于 Robbins LLP</strong>：作为股东权益诉讼的公认领导者，Robbins LLP 的律师和员工自 2002 年以来一直致力于帮助股东追回损失、改善公司治理结构，并追究公司高管的错误行为。</p>
</div><p>To be notified if a class action against Capricorn Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.</p>
<div class="lb-trans"><p>如果希望在针对 Capricorn Therapeutics, Inc. 的集体诉讼达成和解时收到通知，或在公司高管参与不当行为时免费接收警报，请立即注册 Stock Watch。</p>
</div><p>Attorney Advertising. Past results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。过去的结果并不保证类似的结果。</p>
</div><p>www.robbinsllp.com</p>
<div class="lb-trans"><p>www.robbinsllp.com</p>
</div><p>SOURCE Robbins LLP</p>
<div class="lb-trans"><p>来源 Robbins LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzMwJk5ld3NJdGVtSWQ9TEEzODA2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MzAxMTIyUFJfTkVXU19VU1BSX19fX19MQTM4MDY0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA38064&amp;Transmission_Id=202507301122PR_NEWS_USPR_____LA38064&amp;DateId=20250730"/></p>

11:22 ET
			
			
				Robbins LLP Reminds CAPR Investors with Large Losses of the Class Action Lawsuit on Behalf of  Capricor Therapeutics, Inc. Shareholders

Robbins LLP 提醒 CAPR 投资者，若遭受重大损失，可代表 Capricor Therapeutics, Inc.的股东参与集体诉讼